Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 165 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Uterine Leiomyoma Clear all

Conditions: Uterine Fibroids, Menorrhagia, Endometriosis
Interventions: conventional laparoscopic hysterectomy, robotic assisted laparoscopic hysterectomy; Procedure
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Uterine Fibroids
Interventions: ExAblate Treatment UF V2; Device
Lead sponsor: InSightec; Industry
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 8
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 5 more

Conditions: Fibroid Uterus, Quality of Life
Interventions: Intraoperative contact ultrasonography; Procedure
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 21 Years to 45 Years · Female only
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Weston, Florida

Conditions: Leiomyoma
Interventions: Dexamethasone, Saline; Drug
Lead sponsor: University of Miami; Other
Eligibility: 20 Years to 50 Years · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Uterine Fibroids
Interventions: Proellex; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 13
States / cities: San Diego, California • Sarasota, Florida • Atlanta, Georgia + 9 more

Conditions: Uterine Fibroids, Endometriosis
Interventions: Relugolix Combination Tablet; Drug
Lead sponsor: Sumitomo Pharma Switzerland GmbH; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 120
States / cities: Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 98 more

Conditions: Leiomyoma
Interventions: ExAblate 2000; Device
Lead sponsor: InSightec; Industry
Eligibility: Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Symptomatic Uterine Fibroids and Adenomyosis
Interventions: IV Ibuprofen, IV Acetaminophen, Intravenous placebo/Intravenous placebo; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years to 60 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Los Angeles, California • Santa Monica, California

Conditions: Fibroid Uterus, Fibroid Tumor, Leiomyoma, Fibromyoma, Leiomyoma, Uterine
Interventions: Simvastatin 40mg, Placebo 40 mg; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Metrorrhagia, Pelvic Pain, Menorrhagia, Leiomyoma
Interventions: Myfembree Oral Product; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 6
States / cities: Chicago, Illinois • Flossmoor, Illinois • Orland Park, Illinois + 1 more

Conditions: Menorrhagia, Uterine Fibroids
Interventions: Doppler-Guided Uterine Artery Occlusion Device (DUAO); Device
Lead sponsor: Ethicon, Inc.; Industry
Eligibility: 25 Years to 50 Years · Female only
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 9
States / cities: Phoenix, Arizona • Fort Lauderdale, Florida • Southfield, Michigan + 6 more

Conditions: Leiomyoma
Interventions: EcoSac 400 ECO-T; Device
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Park Ridge, Illinois

Conditions: Surgery
Interventions: LapBox Manual Containment System, Standard of Care Specimen Bag; Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Uterine Fibroids
Interventions: ExAblate; Device
Lead sponsor: InSightec; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 8
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 5 more

Conditions: Urinary Tract Infection, Leiomyoma
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 860 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Fibroids, Uterine, Fluid Deficit, Hysteroscopy / Methods
Interventions: Misoprostol Tabets, Placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Endometriosis, Fibroids, Adenomyosis, Pelvic Pain, Abnormal Uterine Bleeding, Adnexal Mass, Minimally Invasive Gynecologic Surgery, Hysterectomy, Myomectomy, Ovarian Cystectomy, Adnexal Surgery
Interventions: educational video; Other
Lead sponsor: UConn Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Fibroid Uterus, Endometriosis, Uterus Myoma, Uterine Fibroid, Uterine Adenomyosis, Endometrial Cyst, Uterine Cyst
Interventions: ICG; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Uterine Fibroids - 1St Diagnosis, Uterine Fibroids Affecting Pregnancy, Uterine Fibroid Degenerated
Interventions: Holistic Medicine (HM); Behavioral
Lead sponsor: Virtual Tribunal Monastery; Other
Eligibility: 22 Years and older · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Anchorage, Alaska

Conditions: Leiomyoma
Interventions: CDB-2914; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 33 Years to 50 Years · Female only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Uterine Fibroids, Uterine Leiomyomas
Interventions: ExAblate 2000; Device
Lead sponsor: InSightec; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 4
States / cities: La Jolla, California • Burlington, Massachusetts • Kalamazoo, Michigan + 1 more

Conditions: Uterine Fibroid, Arteriovenous Malformations, Hypervascular Tumors, Benign Prostatic Hyperplasia
Interventions: Treatment with HydroPearl via radial access; Device
Lead sponsor: Terumo Medical Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 6
States / cities: Los Angeles, California • Chicago, Illinois • St Louis, Missouri + 3 more

Conditions: Symptomatic Uterine Fibroids
Interventions: Global Fibroid Ablation (GFA), Abdominal or Laparoscopic Myomectomy, Uterine Artery Embolization (UAE); Procedure
Lead sponsor: Acessa Health, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2025
U.S. locations: 9
States / cities: Santa Monica, California • Walnut Creek, California • Augusta, Georgia + 6 more

Conditions: Uterine Fibroids, Infertility
Interventions: surgery utilizing V-Loc suture; Device
Lead sponsor: The Advanced Gynecologic Surgery Institute; Other
Eligibility: 18 Years to 42 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Naperville, Illinois

Search by objective public record fields.

Study Comparing Conventional vs. Robotic-assisted Laparoscopic Hysterectomy

ExAblate UF V2 System for the Treatment of Symptomatic Uterine Fibroids

Intraoperative Ultrasound in Laparoscopic or Robotic Myomectomy Patients

Dexamethasone for Post Uterine Artery Embolization Pain

Safety and Efficacy of 25 and 50 mg Doses of Proellex® in Treating the Recurrence of Uterine Fibroid Symptoms

A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis

Magnetic Resonance (MR) Guided Focused Ultrasound Surgery of Uterine Fibroids

Effectiveness of IV Acetaminophen and IV Ibuprofen in Reducing Post Procedural Pain in the UFE Procedure

Effects of Simvastatin on Uterine Leiomyoma Size

Surgical Myomectomy Followed by Oral Myfembree Versus Standard of Care Trial (SOUL)

Doppler-Guided Uterine Artery Occlusion (DUAO) Device for Fibroid Related Bleeding

Power Morcellation Systems for Laparoscopic Hysterectomy and Myomectomy

LapBox® Manual Containment System

Safety Study of ExAblate for the Treatment of Uterine Fibroids

Lower Urinary Tract Infection (UTI) Evaluation in Women With Uterine Leiomyomata

Effect of Misoprostol on Fluid Deficit Volume in Hysteroscopic Myomectomy

Impact of Educational Videos on Pre-operative Anxiety

ICG to Assess Ovarian Perfusion

Holistic Medicine Treatment of Uterine Fibroids-Adults

Treatment of Uterine Fibroids With CDB-2914, an Experimental Selective Progesterone Receptor Antagonist

MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids: Software V4.2 Validation

An Observational Study of Radial Access Embolization Procedures Using HydroPearl Microspheres

Post Market TRUST - U.S.A. Study

a Study to Evaluate Adhesion Risk in Fertility Patients' Status Post Laparoscopic Myomectomy.